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Enhancing Specific Disruption of 
Intracellular Protein Complexes 
by Hydrocarbon Stapled Peptides 
Using Lipid Based Delivery
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D. P. Lane  1 & C. J. Brown1
Linear peptides can mimic and disrupt protein-protein interactions involved in critical cell signaling 
pathways. Such peptides however are usually protease sensitive and unable to engage with intracellular 
targets due to lack of membrane permeability. Peptide stapling has been proposed to circumvent these 
limitations but recent data has suggested that this method does not universally solve the problem 
of cell entry and can lead to molecules with off target cell lytic properties. To address these issues a 
library of stapled peptides was synthesized and screened to identify compounds that bound Mdm2 
and activated cellular p53. A lead peptide was identified that activated intracellular p53 with negligible 
nonspecific cytotoxicity, however it still bound serum avidly and only showed a marginal improvement 
in cellular potency. These hurdles were overcome by successfully identifying a pyridinium-based cationic 
lipid formulation, which significantly improved the activity of the stapled peptide in a p53 reporter cell 
line, principally through increased vesicular escape. These studies underscore that stapled peptides, 
which are cell permeable and target specific, can be identified with rigorous experimental design and 
that these properties can be improved through use with lipid based formulations. This work should 
facilitate the clinical translation of stapled peptides.
Interest in chemical modifications that enable the translocation of peptides into cells is spurred on by the increas-
ing use of biologics, peptides, proteins and their mimetics as tools in research and therapeutic development1–3. 
Several different covalent linkages have been used to stabilize the receptor bound helical conformations of pep-
tides in solution4. The hydrocarbon ‘staple’, which consists of the coupling together of 2 olefin bearing non-natural 
amino acids located at suitable positions along the peptide, is one such increasingly used modification and has 
been shown to enable cellular uptake, increased proteolytic stability and improved distribution in animal models 
of a variety of peptides5–7. One of the main features of stapled peptides is their ability to potently bind the large 
and relative flat polar surface areas that are found in a large majority of protein-protein interactions (PPIs)8, which 
are intractable to small molecules. A large proportion of therapeutically relevant PPIs are intracellular and many 
are mediated by an α-helix in one of the proteins constituting the interface. This makes them attractive targets for 
the development of stapled peptides9.
The p53: Mdm2 interaction is a clinically relevant example of a PPI mediated by an α-helix10. p53 is a tumor 
suppressor protein that is frequently inactivated in human cancers by over-expression of Mdm2, which targets 
p53 for proteosomal degradation via its E3 ubiquitin ligase activity11. Inactivation of p53 allows malignant cells to 
escape cell cycle arrest and apoptosis11. The unfolded transactivation domain of p53 forms a helix when it binds 
Mdm2, where upon 3 conserved residues (F19, W23, L26) are buried into a hydrophobic cleft upon the surface of 
Mdm212. Several stapled peptides have been designed by several groups against Mdm2 using binding sequences 
either derived from the known p53 binding epitope or isolated using phage display experiments13, 14. A stapled 
peptide antagonist (ALRN-6924) of the Mdm2:p53 interaction is undergoing phase 1 clinical trials (ClinicalTrial.
gov). Extensive research elsewhere has also been directed towards developing stapled peptides against a variety of 
targets such as EZH and Bcl-215–17.
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The potential of stapled peptides to be developed as therapeutic compounds have been restricted by their lack 
of ubiquitous cellular permeability18, avid serum binding7, and indications that their biological and in vivo activ-
ities are the results of non-specific modes of actions, which are target independent19. This brings into question 
whether or not stapled peptides engage their intracellular targets and enter cells in the absence of cell membrane 
disruption, which gives rise to cytotoxicity and other nonspecific signals that can be falsely concluded to be mech-
anistically on target19. To address these concerns we synthesized a library of stapled peptides, using the helically 
stabilized Mdm2 binding peptide (sMTIDE-02) developed by ourselves as a template6, and stringently screened 
for compounds with improved cellular activity and negligible cytotoxicity, as a function of cell membrane disrup-
tion. The cellular permeability and mechanistic action of these peptides was then confirmed by measuring the dis-
ruption of intracellular p53:Mdm2 complexes using a live cell protein-protein interaction BRET (bioluminescent 
resonance excitation transfer assay) based assay20. The top ranked compound identified however only showed a 
marginal improvement in its cellular potency compared to sMTIDE-02, whilst still exhibiting substantial serum 
binding. To overcome these hurdles and enhance its cellular delivery, various lipid based preparations were then 
explored in combination with the newly identified optimized stapled peptide21–26. This lead to the identification 
of a pyridinium amphiphile cationic lipid formulation that enhanced the activity of the p53 activating stapled 
peptide by an order of magnitude, principally through more efficient vesicular escape into the cytoplasm.
Results and Discussion
High Stringency Library Screening for Stapled p53 Re-Activating Peptides with Improved 
Cellular Activity and Decreased Cyto-toxicity. A library of stapled peptides targeting the p53:Mdm2 
interaction, using sMTIDE-02 as a template, was synthesized and assessed for binding to Mdm2 using a com-
petitive fluorescence anisotropy (FA) assay, for p53 activity in a reporter cell line (T22 cells) and for their ability 
to disrupt cell membranes of the p53 reporter cells using a LDH (lactate dehydrogenase) release assay (Fig. 1A 
and B). LDH release was measured within 2 hours after compound treatment to differentiate cell membrane 
disruption from the later stages of apoptosis, and from effects related to the onset of p53 transcriptional activity. 
The p53 reporter assay and LDH release assays were also performed in the presence and absence of serum, the 
former to reflect more physiologically relevant conditions and the latter to enable identification of sequences 
unaffected by sequestration to components in the serum. In the absence of serum a significant proportion of 
the peptide library induced p53 activity (~ over 50% of the screened peptides caused induction of p53 activity 
over a normalized value of 0.5) at the lowest treatment concentration used (12.5 µM), whilst in the presence of 
10% serum a dramatic overall decrease in the potency of the library was observed indicating that serum binding 
is a common property of stapled peptides (Fig. 1A). In addition, a large proportion of the peptides (~20%) in 
the library also exhibited cytotoxicity (LDH leakage) in the absence of serum (Fig. 1B), which was significantly 
reduced in the presence of serum (to ~ 5%). This confirms that LDH leakage, which is a proxy measurement for 
cell membrane disruption, correlates to the increased concentration of free peptide when it is unbound to serum. 
sMTIDE-02 and ATSP-7041, reported by ourselves6 and Aileron7 independently of each other, were also included 
in the library and confirmed to disrupt the Mdm2:p53 complex in vitro and to activate p53 in the T22 cell based 
reporter assay. However, under no serum conditions, in agreement with published findings19, both peptides also 
induced LDH leakage indicating destabilization of the cell membrane alongside p53 activation, an undesirable 
activity indicating the occurrence of p53 independent effects or potential off-target mechanistic activation by 
cellular stress.
To choose the peptide with the most desirable properties i.e. high induction of p53 under physiological con-
ditions and negligible cyto-toxicity, we carefully selected the compound that induced the highest amount of p53 
activity in the presence of serum and also caused no measurable LDH release in the absence of FCS. This resulted 
in the identification of the VIP-82 compound (Ac-KK-Ahx-TSFR8EYWALLS5ENF-NH2, R8 = (R)-2-(7′octenyl) 
alanine and S5 = (S)-2-(4′-pentenyl) alanine), which differed from the initial sMTIDE-02 template sequence 
with a N-terminal di-lysine extension via an aminohexinoic linker to improve solubility and a C-terminal exten-
sion (ENF) to exploit a newly discovered interaction site on the surface of Mdm227. In comparison to the pre-
viously reported stapled Mdm2 binding peptides (sMTIDE-02 and ATSP-7041), the Kd determined for VIP-82 
(24.4 ± 2.3 µM, Table S1) binding to Mdm2 was marginally stronger than that for sMTIDE-02 (34.35 ± 2.0 µM, 
Table S1), but was significantly weaker than the Kd determined for ATSP-7041 (7.4 ± 1.5 µM, Table S1). However 
VIP-82 (EC50 = 0.8 ± 0.1 µM) was more efficacious in inducing p53 activity in the T22 p53 reporter cells than 
both sMTIDE-02 and ATSP-7041 (EC50s of 3.5 ± 0.3 µM and 1.7 ± 0.1 µM, respectively) in the absence of serum 
(Fig. 2A and B, Table 1). EC50s were also determined in the presence of 10% FCS, which revealed that the ATSP-
7041 was the least effected by serum binding amongst the 3 peptides (Table 1) and the most potent activator 
of p53 under serum conditions (Fig. 2A and B). However VIP-82 more importantly, unlike ATSP-7041 and 
sMTIDE-02, did not cause any measurable LDH release in the absence of serum indicating decreased cellular 
toxicity arising from cell membrane disruption, as well as eliminating this as a potential mode of p53 activation 
for VIP-82 (Fig. 2C and D).
Interestingly, the onset of p53 activity for ATSP-7041 and sMTIDE-02 under serum free conditions still 
occurred at concentrations below the threshold required for the induction of LDH release, indicating that gross 
destabilization of the membrane by these compounds also does not directly elicit p53 activity. To conclusively 
confirm that the induction of p53 transcriptional activity in T22 p53 reporter assays is not driven by cellular stress 
mechanisms e.g. cell membrane perturbation or other unknown factors, negative control peptides were carefully 
designed for sMTIDE-02, ATSP-7041 and VIP-82. To achieve this, the 3 residues responsible for the interaction 
of the peptides with Mdm2 were scrambled, in order to abrogate binding to Mdm2, and the remainder of the 
sequence left unchanged. Scrambling was used rather than the introduction of alanine point mutants to generate 
control peptides, as this ensured minimal perturbation of the physiochemical parameters and maintained the 
amphipathicity of the stapled peptides (Fig. 1C), a variable critical in the cellular entry of stapled peptides28. 
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The new control analogues (sMTIDE-02SCRAM, ATSP-7041SCRAM and VIP-82SCRAM) showed no binding against 
Mdm2 in the FA competition assay and induced no p53 activity when tested on T22 cells (Table 1 and Table S1). 
Figure 1. (A) Results for the screening of a 52 membered stapled peptide library using the T22 p53 reporter 
cell based assay. The library was screened either in the presence (10%) or absence of FCS (fetal calf serum) at 
3 different concentrations to capture weak and strong inducers of p53 activation. (B) Results for screening the 
library using the CYTO-TOX LDH release assay (Promega) to assess for membrane destabilization. The library 
was screened either in the presence (10%) or absence of FCS at three different concentrations to capture weak 
and strong LDH releasers. (C) A helical wheel representation of the sMTIDE-02 template sequence used for the 
design of the peptide library. The peptides in the library are amphipathic in nature with a hydrophobic aliphatic 
chain running down one face of the helix, the hydrophobic Mdm2 conserved binding motif running down the 
other and the remainder of the molecule being slightly more polar in character. * indicates the location of VIP-
82 amongst the stapled peptides screened.
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However, both sMTIDE-02SCRAM and ATSP-7041SCRAM, unlike their unscrambled counterparts, also induced 
LDH release in the presence of serum as well as in its absence. (Fig. 2E and F, Table 1). The ability of sMTIDE-
02SCRAM and ATSP-7041SCRAM to efficiently disrupt cellular membranes, without inducing cellular p53 activity or 
binding to Mdm2 in vitro, confirms that p53 activating peptides act mechanistically through the disruption of the 
intracellular Mdm2:p53 complex and not through membrane disruption.
Stapled Peptides Specifically Disrupt the Intracellular p53:Mdm2 Complex within Live 
Cells. To verify that the molecular mechanism of p53 activation was due to intracellular engagement of Mdm2 
by the stapled peptides (VIP-82, ATSP-7041 and sMTIDE-02) and through their disruption of the Mdm2:p53 
Figure 2. sMTIDE-02, ATSP-7041 and VIP-82 were titrated on to T22 p53 reporter cells and p53 
transcriptional activation assessed (A) in the presence (10% FCS) or (B) absence of serum. (C and D) Identical 
titrations were performed on T22 cells and LDH release measured. Scrambled variants of sMTIDE-02, ATSP-
7041 and VIP-82 (designated with scram in superscript) were synthesized, where the residues involved in 
the conserved binding motif (F19, W23, L26) were interchanged with each other to abrogate binding to p53. 
sMTIDE-02SCRAM, ATSP-7041SCRAM and VIP-82SCRAM were titrated on to p53 reporter T22 cells (E) in the 
presence (10%) and (F) absence of serum and assessed for p53 activation and LDH release. p53 activations 
profiles are shown in the insets.
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complex a nanoBRET (Bioluminescence Resonance Excitation Transfer, PROMEGA) live cell assay was used20. 
The p53:Mdm2 NanoBRET System is a proximity-based assay that can detect protein interactions by measuring 
energy transfer from a bioluminescent luciferase protein donor (nanoLUC, Promega), which is fused to p53, to a 
fluorescent protein acceptor (HaloTag, PROMEGA) that is joined to Mdm2. Both constructs are transiently trans-
fected into a cell population, which are then treated with a cell permeable fluorogenic substrate that covalently 
labels the HaloTag, and causes a BRET signal to be generated. This signal is only generated when the Mdm2 and 
p53 interact with each other and bring the nanoLUC and HaloTag into the local vicinity of each other, enabling 
the transfer of the bioluminescence signal to the fluoorphore. When the Mdm2 and p53 complex is disrupted by a 
cell accessible molecule the fusion proteins are no longer in proximity to each other and the signal is lost.
The p53 activating stapled peptides (sMTIDE-02, ATSP-7041, VIP-82), upon titration of HEK293 cells in 
physiologically relevant high serum conditions, all efficiently disrupted the transfected intracellular Mdm2:p53 
complexes (Fig. 3A,C and E) in the absence of LDH release, (Figure S1) confirming that all three compounds were 
cell permeable and that mechanism of p53 action is indeed through specific inhibition of Mdm2. The p53:Mdm2 
NanoBRET live cell experiments were then repeated in serum free conditions where a substantial improvement 
in the IC50s of the stapled peptides occurred, with 4.5-fold, 4-fold and 9-fold improvements seen for the IC50s 
of VIP-82, ATSP-7041 and sMTIDE-02, respectively (Fig. 3B,D and F, Table 2). These findings further confirm 
the attenuating effect of stapled peptide sequestration by binding to serum components. However, ATSP-7041 
and sMTIDE-02, apart from showing improved cellular permeability in the absence of serum components, also 
induced significant amounts of LDH release, unlike VIP-82 which still remained inert (Figure S1). However, 
as observed in the T22 cell based p53 reporter titrations, disruption of the intracellular Mdm2:p53 complex 
occurred at concentrations below that required for LDH release, providing more evidence that cell membrane 
disruption has no role in the activation of p53.
The inactive scrambled analogues were also titrated in the nanoBRET assay and caused negligible inhibition 
of Mdm2 binding to p53 under high serum conditions. However in the absence of serum, both ATSP-7041SCRAM 
and sMTIDE-02SCRAM did induce disruption of the Mdm2:p53 complex (Fig. 3D and F), which did not occur for 
VIP-82SCRAM. At similar treatment concentrations both compounds also induced significant amounts of LDH 
release (Figure S1), implying that disruption of the cellular membrane enables the release of Mdm2:p53 com-
plexes into the surrounding cell media, whereby the subsequent dilution causes their dissociation and a concom-
itant decrease in the BRET signal. However, more importantly, this nonspecific effect elicited by the scrambled 
analogues occurs at concentrations significantly above the IC50s determined for the active peptides.
Enhancing Cellular Delivery and Intracellular Activity of VIP-82 using a Pyridinium Cationic 
Based Lipid Formulation. VIP-82, despite a 2-fold improvement in its affinity for Mdm2 over the library 
template sequence (sMTIDE-02) and the elimination of its ability to lyse cellular membranes, only showed a mar-
ginal improvement in its potency to reactivate p53 (Fig. 2A,B and D, Table 1). In addition, VIP-82 also displayed 
no significant decrease in its serum binding compared to sMTIDE-02, leading to substantial decreases in its bio-
logical activity in the presence of serum (Fig. 2A, Table 1). To address these limitations we decided to investigate 
several different lipid based formulations: NanoCargo (Tecrea, www.tecrea.co.uk), sterically stabilized micelles 
(SSM)22, 23 constituted from mPEG-2K-DSPE7 (Avanti Polar Lipids, Inc.) and Saint PhD (Synovolux, www.syn-
volux.nl)24, 26. Each of these formulations can either form micelles or liposomes, which either encapsulate or 
interact with their respective cargo, in this case VIP-82, and prevent the compound being sequestered by serum 
components and thus potentially enhancing the compounds cellular delivery.
VIP-82 was initially titrated onto p53 reporter T22 cells in complex with SaintPhD, a proprietary lipid formu-
lation that consists of a pyridinium cationic lipid and DOPE (dioleoylphosphatidylethanolamine) mixture. EC50s 
of p53 activation were then determined in the absence and presence of serum, which revealed a dramatic 4-fold 
and 5-fold improvement over the non-formulated VIP-82, respectively (Fig. 4A and B). These results suggest that 
SaintPhd primarily enhances the uptake of the peptide into cell and that the serum protective effect is smaller. 
The two other formulations were also assessed, both of which caused no significant improvement in the potency 
of VIP-82 in the p53 reporter system (Fig. 4A,B and C). In fact, the SSM formulation completely abrogated 
induction of p53 by the VIP-82 peptide, whilst the NanoCargo formulation had a negligible effect on the peptide’s 
activity in the presence of FCS and even marginally attenuated it in the absence of serum (Fig. 4B). The SSM 
formulation consists of micelles constituted from the pegylated lipid mPEG-2K-DSPE, where the PEG part of 
the molecules form a palisade around a buried hydrophobic lipid core29. The abrogation of the p53 activity by the 
SSM formulation implies that VIP-82 is strongly sequestered and is either interacting with the PEG palisade or 
the hydrophobic cores of the particles, which in turn prevents any potential binding to Mdm2. On the other hand, 
Peptide
P53 Activation (T22 Cells, µM) LDH Release (T22 Cells, µM)
0% FCS 10% FCS 0% FCS 10% FCS
sMTIDE-02 3.5 ± 0.3 18.2 ± 0.7 50.5 ± 1.7 No release
ATSP-7041 1.7 ± 0.1 6.4 ± 0.2 71.8 ± 4.8 No release
VIP-82 0.8 ± 0.1 10.0 ± 0.1 No release No release
sMTIDE-02SCRAM No Activity No Activity 25.1 ± 2.8 105 ± 8.0
ATSP-7041SCRAM No Activity No Activity 191.1 ± 20.1 149.0 ± 10.1
VIP-82SCRAM No Activity No Activity No Release No Release
Table 1. p53ACT50 and LDH50 values were determined from 4 parameter fits to 10 point titration curves.
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Figure 3. Disruption of intracellular Mdm2:p53 complexes were assessed using the nanoBRET assay (Promega) 
and IC50s were determined. Titrations were carried out in pairs between the active stapled peptide and the 
scrambled control variant to determine the window of specificity between targeted disruption of the Mdm2:p53 
complex and the onset of non-specific cellular effects: VIP-82 and VIP-82SCRAM (A) in 10% FCS and (B) 0% FCS, 
sMTIDE-02 and sMTIDE-02SCRAM (C) in 10% FCS and (D) 0% FCS, and ATSP-7041 and ATSP-7041SCRAM in 
(E) 10% FCS and (F) 0% FCS. Titrations were performed on HEK293 cells and nanoBRET signal was measured 
after 4 hours.
Peptide
Mdm2:p53 Complex Disruption 
(HEK293 Cells, µM)
0% FCS 10% FCS
sMTIDE-02 2.3 ± 0.2 17.9 ± 0.2
ATSP-7041 1.1 ± 0.1 4.3 ± 0.2
VIP-82 3.9 ± 0.2 17.5 ± 1.3
sMTIDE-02SCRAM 11.9 ± 0.5 NA
ATSP-7041SCRAM 17.92 ± 1.4 NA
VIP-82SCRAM NA NA
Table 2. NanoBRET IC50 values determined from 4 parameter fits to 10 point titration curves.
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Figure 4. VIP-82 was formulated with either Saint PhD (Synvolux, Netherlands), Nanocargo (Tecrea, UK) or 
mPEG-2K-DSPE (Avanti Polar Lipids, Inc.) and titrated onto T22 p53 reporter cells in the (A) presence or (B) 
absence of serum. (C) Table displaying EC50s of p53 activation, determined from titration curves produced by 
the p53 reporter assay, for sMTIDE-02, ATSP-7041 and VIP-82 either alone or formulated with SaintPhD. EC50 
values were also determined either in the presence or absence of fetal calf serum. In addition results for VIP-82 
formulated with Nanocargo and DSPE-mPEG2K derived SSMs are also shown. (D) A subset of stapled peptides 
were selected and either formulated with SaintPhD (+) or without (−) and screened at a concentration of 6 µM 
in the presence of 10% fetal calf serum (FCS) using T22 p53 reporter cells.
www.nature.com/scientificreports/
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NanoCargo only attenuated the activity of VIP-82 in the absence of serum and had no effect on the peptide in 
the presence of serum, suggesting that it also interacted with the NanoCargo formulation but much less strongly.
To ensure that the p53 transcriptional activity of VIP-82:SaintPhd was specific and on-target LDH release 
assays were performed that showed little measurable cell membrane disruption (Figure S2). Small amounts of 
release were however detected at a peptide concentration of 6 µM in the absence of serum. In addition VIP-82scram 
was formulated and tested under identical experimental conditions to VIP-82:SaintPhD, which revealed that it 
did not induce any p53 activity or LDH release (Figure S2) confirming specific reactivation of p53. ATSP-7041 
and sMTIDE-02 were also re-constituted with SaintPhD, where interestingly sMTIDE-02 showed no improve-
ment in the absence of serum but did show a significant increase in potency in the presence of serum demonstrat-
ing the SaintPhD can prevent serum sequestration in a sequence specific manner, whilst ATSP-7041 on the other 
hand exhibited marginal improvements under both conditions (Fig. 4C). These results emphasize that the dra-
matic improvements observed for VIP-82 in cellular potency with respect to lipid formulation are also sequence 
dependent. A subset of peptides were further selected and screened against T22 p53 reporter cells, either formu-
lated with or without SaintPhD, at a concentration where none of the compounds activated p53. Several peptides 
were potentiated in a manner similar to VIP-82 demonstrating that other sequences can act synergistically with 
SaintPhD to improve their activity in cell culture.
Saint PhD Increases Stapled Peptide Activity by Enhancing Endosomal Escape. To further 
understand the precise mechanism of improvement of VIP-82:SaintPhD over unformulated peptide we decided 
to incorporate a fluorescein (FAM) fluorophore into the design of the stapled peptide to allow examination of 
the cellular distribution of the peptide. Fluorescein labelled peptides were synthesized for VIP-82, ATSP-7041 
and sMTIDE-02, by addition of FAM to their N-terminus via a β-alanine linker, and then tested in the T22 p53 
reporter assay to ensure that they retained comparable biological activity to their unlabeled analogs, respectively 
(Figure S3). sMTIDE-02FAM displayed no activity under high serum conditions and only marginal activity in the 
absence of serum, whilst the determined EC50s for VIP-82FAM were attenuated 2.5 fold and 4 fold, respectively, 
with regards to VIP-82. However, ATSP-7041FAM retained comparable activity in the T22 p53 reporter assay 
to its unlabeled analogue ATSP-7041. ATSP-7041FAM was then reformulated with Saint PhD, where in contrast 
to ATSP-7041, significant improvements were observed in the EC50s of p53 activation over the unformulated 
peptide (Fig. 5A), further underlining how small molecular changes influence the biological properties of the 
resulting SaintPhd:peptide lipocomplex. ATSP-7041FAM was therefore used to examine the effects of SaintPhD on 
the cellular distribution and uptake of stapled peptides.
Live T22 cells under high serum conditions were pulse labelled with either ATSP7041FAM:Saint PhD (6 µM) or 
unformulated peptide (25 µM) at various times points and examined using confocal microscopy (Fig. 5B and C). 
These concentrations were selected as they induced maximal activity of p53. ATSP7041FAM:Saint PhD and free 
ATSP7041FAM were both initially internalized into the cell via cytoplasmic vesicles, where upon at later time 
points dramatic differences can be seen in the distribution of the peptide (Fig. 5B and C). In the case of ATSP-
7041FAM staining of the vesicles then becomes more intense over time followed by the accumulation of the FAM 
labelled peptide in the nucleus. In contrast, ATSP7041FAM:Saint PhD is rapidly released from the vesicles into 
the interior of the cell resulting in a diffuse cytoplasmic and nuclear stain. These results clearly demonstrate 
that the Saint PhD lipid formulation is enhancing vesicular escape of the stapled peptide and enabling higher 
intracellular levels of ATSP-7041FAM to be reached at much lower treatment concentrations when compared to 
stapled peptide alone. In addition the staining of the nucleus by formulated and unformulated peptides highlights 
that ATSP-7041FAM reaches the correct cellular locality to exert its functional activity. This is further supported 
by the detection of increased nuclear protein expression of both Mdm2 and p53 (Fig. 5D). The SaintPhD lipid 
formulation consists of 2 principal lipid components, the pyridinium cationic amphiphile Saint and the phospho-
lipid DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine), which is neutrally at physiological pH. DOPE 
is a well-known endosomolytic reagent30 and is most likely responsible for the increase in potency of the VIP-
82:SaintPhD lipo-complexes with respect to unformulated VIP-82, after internalization of the complex into the 
cell. DOPE is a zwitterionic lipid, which under the acidic conditions of late endosomes undergoes a lipid phase 
change from lamellar to the inverse hexagonal phase that is disruptive to cellular lipid membrane bilayers31–33, 
enabling VIP-82 to undergo endosomal escape.
Conclusion
The covalent modification of peptides using techniques such as stapling in order to stabilize their secondary 
structure represents an exciting opportunity to develop novel biologically active peptides that target intracellular 
interactions9. In this work we demonstrate that stapled peptides can be identified which interact with Mdm2, 
reactivate p53 and induce no LDH release under high or low serum conditions. We also confirmed the cell per-
meability of stapled peptides and their mechanism of p53 reactivation through the use of a live cell nanoBRET 
intracellular Mdm2:p53 interaction assay. In addition we ascertained that under conditions where stapled pep-
tides induced LDH leakage that p53 re-activation and complex disruption occurred at much lower concentration 
thresholds, indicating that membrane destabilization is not a stress activator of the p53 pathway. The observation 
that p53 activity also does not occur with peptides where Mdm2 binding is abrogated but membrane disruption 
still takes places further corroborates this.
However, despite the isolation of a stapled peptide that caused minimal membrane perturbation with con-
firmed intracellular activity, only a marginal improvement in the potency of p53 activation was gained. This 
was overcome by screening VIP-82 with various lipid based formulations, ranging from micellular to liposomal, 
and identifying a system that prevented sequestration by serum and enhanced cellular uptake. Excitingly this 
enhancement in cellular uptake resulted in an order of magnitude improvement in biological activity as measured 
with p53 reporter cell line. Fluorescence studies further revealed that the main mechanism of this improvement 
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by SaintPhD was vesicular escape (Fig. 5B and C), which enabled the stapled peptide to more efficiently enter the 
cytoplasm and disrupt the p53:Mdm2 complex. However, not all the stapled peptides formulated with this lipid 
based system showed similar levels of enhancement, indicating that the potential synergy of the formulation with 
the compound is sequence dependent. This raises a new avenue of development where peptides can be designed 
in conjunction with lipid based delivery systems to improve their biological properties rather than through itera-
tive rounds of peptide design and staple optimization for marginal gain. In addition the earlier application of lipid 
systems to stapled peptide development will allow more rapid identification of conditions that prevent peptide 
aggregation and improve their solubility, lowering the barrier of entry into animal studies.
The assays outlined in this study provide a robust framework for the identification and validation of sta-
pled peptides that disrupt specific intracellular complexes. The results presented here should re-invigorate 
research into stapled peptides and further enable their transition into the clinic. The application of new delivery 
Figure 5. (A) ATSP-7041FAM either formulated with Saint PhD or non-formulated was titrated onto T22 p53 
reporter cells in the presence or absence of serum and p53 activity determined. (B) Time course experiment 
showing cellular uptake of non-formulated ATSP-7041FAM at a peptide concentration of 25 µM into T22 cells in 
the presence of 10% FCS, which have been pulse labeled at different time intervals. (C) Time course experiment 
showing cellular uptake of ATSP-7041FAM:SAINTPhD at a peptide concentration of 6 µM into T22 cells with 
10% FCS present, which have been pulse labeled at different time intervals. (D) Fixed T22 cells were stained for 
Mdm2 and p53 protein levels after 4 hour treatment with either 1% DMSO or 25 uM ATSP-7041 in the presence 
of 10% FCS.
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technologies, such as lipid formulation, to improve the biological activity and biochemical properties of stapled 
peptides represents a new and exciting frontier in the development of these compounds.
Materials and Methods
Peptide Synthesis and Purification. See supplementary information.
Mdm2 (1–125) protein Expression and Purification. See supplementary information.
Mdm2 Competitive Fluorescence Anisotropy Assay and Kd Determination. See supplementary 
information.
Preparation of Stapled Peptide Stock and Working Solutions. See Supplementary information.
p53 Gene Reporter Assays. T22 cells, which were stably transfected with a p53 responsive β-galactosidase 
reporter, were seeded into a 96-well plate at a cell density of 8000 cells per well. Cells were also maintained in 
Dulbecco’s Minimal Eagle Medium (DMEM) with 10% fetal calf serum (FCS) and 1% (v/v) penicillin/strepto-
mycin. The cells were incubated for 24 hours and followed by cell media removal and replacement with 90 µl of 
fresh DMEM either containing 10% FCS or 0% FCS. 10 µl of each compound was then added directly to each well 
and incubated for 18 hours. Final working concentration of DMSO was 1% v/v. Corresponding negative con-
trol wells with 1% DMSO only were also prepared. β-galactosidase activity was detected using the FluoReporter 
LacZ/Galactosidase Quantitation kit (Invitrogen) as per manufacturer’s instructions. Measurements were carried 
out using an Envision multiplate reader (Perkin-Elmer). Maximum p53 activity was defined as the amount of 
β-galactosidase activity induced by 25 µM Nutlin. This was was then used to normalize the experimental results.
Lactate (LD) Dehydrogenase Release Assay. T22 cells or HEK 293 cells were seeded into a 96-well 
plate at a cell density of 5000 cells per well. Cells were maintained in Dulbecco’s Minimal Eagle Medium (DMEM) 
with 10% fetal bovine serum (FBS) and 1% (v/v) penicillin/streptomycin. The cells were incubated for 24 hours 
followed by cell media removal and addition of 90 µl of DMEM either with or without 10% FCS. Cells were 
then treated with compounds/peptide for 2 hours in DMEM with or without 10% FBS. Final working concen-
tration of DMSO was 1% v/v. Corresponding negative control wells with 1% DMSO only were also prepared. 
Cytosolic lactate dehydrogenase release was detected using the cytoTox 96® non-radioactive cytotoxicity Assay 
kit (Promega) as per manufacturer’s instructions. Measurements were carried out using an Envision multiplate 
reader (Perkin-Elmer). Maximum LDH release was defined as the amount of LDH released when cells were lysed 
in the presence of 0.1% TRITON X-100 and was used to normalize the results.
Peptide Formulation. See supplementary information.
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